153 related articles for article (PubMed ID: 37482177)
1. Comparison of subcutaneous and oral methotrexate initiation in rheumatoid arthritis in current practice.
Vidal-Montal P; Thomas M; Combier A; Steelandt A; Miceli-Richard C; Molto A; Narváez J; Nolla JM; Allanore Y; Avouac J
Joint Bone Spine; 2023 Dec; 90(6):105620. PubMed ID: 37482177
[No Abstract] [Full Text] [Related]
2. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
Bathon JM; Martin RW; Fleischmann RM; Tesser JR; Schiff MH; Keystone EC; Genovese MC; Wasko MC; Moreland LW; Weaver AL; Markenson J; Finck BK
N Engl J Med; 2000 Nov; 343(22):1586-93. PubMed ID: 11096165
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics.
Sharma P; Scott DG
Drugs; 2015 Nov; 75(17):1953-6. PubMed ID: 26474779
[TBL] [Abstract][Full Text] [Related]
4. Tapering subcutaneous methotrexate causes more disease flares compared with tapering oral administration in established rheumatoid arthritis patients.
Looijen AEM; van Mulligen E; van der Helm-van Mil AHM; de Jong PHP
Rheumatology (Oxford); 2022 Aug; 61(8):e216-e218. PubMed ID: 35266525
[No Abstract] [Full Text] [Related]
5. Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?
Alsaeedi S; Keystone EC
Nat Rev Rheumatol; 2014 Oct; 10(10):578-9. PubMed ID: 25090946
[No Abstract] [Full Text] [Related]
6. [Methotrexate: advantages of subcutaneous administration].
Krüger K
Z Rheumatol; 2008 Jul; 67(4):332-3. PubMed ID: 18443809
[No Abstract] [Full Text] [Related]
7. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of rheumatoid arthritis.
Marcus DM
Ann Rheum Dis; 2014 Sep; 73(9):e56. PubMed ID: 24938284
[No Abstract] [Full Text] [Related]
8. Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis.
Tanaka Y
Mod Rheumatol; 2023 Jul; 33(4):633-639. PubMed ID: 36525530
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
Bianchi G; Caporali R; Todoerti M; Mattana P
Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
[TBL] [Abstract][Full Text] [Related]
10. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.
Schiff M; Jaffe J; Freundlich B; Madsen P
Expert Rev Med Devices; 2014 Sep; 11(5):447-55. PubMed ID: 24934630
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate revisited: considerations for subcutaneous administration in RA.
Jay R
Clin Rheumatol; 2015 Feb; 34(2):201-5. PubMed ID: 25433918
[TBL] [Abstract][Full Text] [Related]
12. Accelerated cutaneous nodulosis during methotrexate therapy in a patient with rheumatoid arthritis.
Williams FM; Cohen PR; Arnett FC
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 2):359-62. PubMed ID: 9703153
[TBL] [Abstract][Full Text] [Related]
13. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
[TBL] [Abstract][Full Text] [Related]
14. Response to D.M. Marcus's comment on the TRIFRA study (comparison of Tripterygium wilfordii Hook F vs methotrexate in the treatment of active rheumatoid arthritis).
Lv QW; Zhang W; Shi Q; Zheng WJ; Lipsky PE; Zhang X
Ann Rheum Dis; 2014 Sep; 73(9):e57. PubMed ID: 25085980
[No Abstract] [Full Text] [Related]
15. Methotrexate use in rheumatoid arthritis.
O'Dell JR
Rheum Dis Clin North Am; 1997 Nov; 23(4):779-96. PubMed ID: 9361155
[TBL] [Abstract][Full Text] [Related]
16. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al.
Raghu P; Grover PS; Kumar A
Arthritis Rheum; 2008 Jul; 58(7):2209; author reply 2209-10. PubMed ID: 18576338
[No Abstract] [Full Text] [Related]
17. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
[TBL] [Abstract][Full Text] [Related]
18. Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
Yadlapati S; Efthimiou P
Rheumatol Int; 2016 May; 36(5):627-33. PubMed ID: 26936262
[TBL] [Abstract][Full Text] [Related]
19. [Subcutaneous self-administration of methotrexate in rheumatoid arthritis].
Huisman AM; Schouten JP; van Paassen HC; Wouters JM; Jacobs JW
Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1564-5. PubMed ID: 8765767
[No Abstract] [Full Text] [Related]
20. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.
Schiff MH; Sadowski P
Rheumatol Int; 2017 Feb; 37(2):213-218. PubMed ID: 28012023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
